-
The efficacy and safety study of oral direct thrombin Inhibitor Ximelagatran Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) was presented by Dr. Jonathan Halperin.
-
Studies of selected patients with ischemic cardiomyopathy have shown improved survival with the use of prophylactic implantable cardioverter
defibrillators (ICD). Thus, DEFibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) was designed to test the survival benefit of ICDs in patients with heart failure but without coronary artery disease.
-
Dr. Joseph Ornato presented the Public Access Defibrillation (PAD) study, which evaluated the efficacy of out-of-hospital cardiac arrest treatment by cardiopulmonary resuscitation (CPR) alone vs CPR plus
use of an automatic external defibrillator (AED) performed by trained laypersons.
-
In the Valsartan in Acute Myocardial Infarction Trial (VALIANT) the angiotensin II receptor blocker (ARB) valsartan (V) was evaluated in 14,703 high-risk acute MI patients to determine its efficacy and safety
profile compared to the ACE inhibitor captopril (C).
-
Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) is a prospective, randomized, controlled trial assessing the effectiveness of an intensive or aggressive lipid-lowering approach
(atorvastatin 80 mg) to a moderate one (pravastatin 40 mg).
-
A high saturated-fat and no-starch diet resulted in modest weight loss without negative effects on serum lipid levels; weight loss can be continued for up to a year with such a diet.
-
A consensus panel updates recent understanding about the causes and treatment in common neuropathic pain problems.
-
The study found that high-intensity warfarin therapy was not necessary for the prevention of recurrent thrombosis in the APA syndrome.
-
A majority of gastric fundic polyps are benign. Their presence in unscreened individuals older than 50 might warrant colonoscopy.
-
The FDA has approved tadalafil, the third phosphodiesterase type 5 inhibitor (PDE5) for the treatment of erectile dysfunction.
